Other languages Perspective Therapeutics, Inc.

Equities

CATX

US46489V1044

Market Closed - Nyse Other stock markets 04:10:00 2024-05-10 pm EDT			5-day change	1st Jan Change
1.75 ^USD	-2.78%		-3.31%	+335.32%

May. 09	Cantor Fitzgerald Starts Perspective Therapeutics With Overweight Rating	MT
Apr. 30	Perspective Therapeutics, Inc. Announces the Selection of Investigational Product VMT-a-NET for the Treatment of Certain Patients with Neuroendocrine Tumors by the U.S. Food and Drug Administration to Participate in the Chemistry	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Perspective Therapeutics, Inc. Announces the Selection of Investigational Product VMT-a-NET for the Treatment of Certain Patients with Neuroendocrine Tumors by the U.S. Food and Drug Administration to Participate in the Chemistry	Apr. 30
Perspective Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28
Perspective Therapeutics, Bristol-Myers Squibb Collaborate on Melanoma Combination Study	Mar. 18
Perspective Therapeutics, Inc. Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb)VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma	Mar. 18
Sector Update: Health Care Stocks Softer in Afternoon Trading	Mar. 04
Perspective Therapeutics to Raise $87.4 Million in Private Placement	Mar. 04
Perspective Therapeutics, Inc. completed the acquisition of Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey from Progenics Pharmaceuticals, Inc.	Feb. 29
Perspective Therapeutics, Inc. Introduces Pre-Targeting Theranostic Technology Platform	Feb. 01
Perspective Therapeutics Closes $89.8 Million Public Offering, Concurrent Private Placement	Jan. 22
Perspective Therapeutics to Raise Nearly $81 Million via Public Offering, Private Placement	Jan. 18
Sector Update: Health Care Stocks Mixed Premarket Thursday	Jan. 18
Perspective Therapeutics Launching Public Offering	Jan. 17
Perspective Therapeutics, Inc. Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs	Jan. 17
Lantheus Holdings Signs Share Purchase, Licensing Deals With Perspective Therapeutics	Jan. 09
Perspective Therapeutics, Inc. Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing Capability	Jan. 09
Sector Update: Health Care Stocks Softer Friday Afternoon	Jan. 05
Perspective Therapeutics Gains After Licensing Cancer Treatment from Mayo Clinc	Jan. 05
Perspective Therapeutics, Inc. Announces Exclusive License Agreement with Mayo Clinic for New Radiopharmaceutical Platform for Prostate Cancer Treatment	Jan. 05
Perspective Therapeutics, Inc. Announces First Patient Dosed in A Phase 1 Study Of212pb)Vmt-A-Net to Treat Refractory or Relapsed Neuroendocrine Tumors	Dec. 07
Perspective Therapeutics, Inc. Announces First Ever Human SPECT Imaging of Pb-212 with VMT-a-NET by Clinical Collaborators in Germany	Nov. 28

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Perspective Therapeutics, Inc.

Equities

CATX

US46489V1044

Other languages

Filters